logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for global professionals · Tuesday, July 7, 2026 · 924,940,185 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Companies News  •••  Topics  •  Countries  •  U.S. States

Cytokinetics News Monitoring

  • Published on 00:46 GMT

    First Half 2026 Recap - Cardiology

    Although recent months have seen a substantial uptick in approvals, the first half of 2026 was a relatively quiet period for the US Food and Drug Administration (FDA). However, this dearth of regulatory updates was balanced out by a significant number of …

    Source: Consultant Live - Pending
  • Published on Jul 6, 2026

    Which Is the Better Long-Term Buy: iShares' Small-Cap IWM or Invesco's Tech-Heavy QQQ?

    Key Points iShares Russell 2000 ETF targets small-cap growth and value stocks, while Invesco QQQ Trust, Series 1 focuses on the largest non-financial leaders on the Nasdaq. Invesco QQQ Trust, Series 1 carries a slightly lower expense ratio of 0.18% …

    Source: Nasdaq - Neutral
  • Published on Jun 16, 2026

    Edgewise data power rival to BMS and Cytokinetics toward phase 3

    Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics. BMS’ Camzyos and Cytokinetics’ Myqorzo are approved …

    Source: Fierce Biotech - Neutral
  • Published on Jun 17, 2026

    Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short

    Edgewise Therapeutics’ investigational drug improved hemodynamic and biomarker outcomes in patients with hypertrophic cardiomyopathy, but the degree of benefit seems to have left investors underwhelmed. The Colorado biotech dipped as much as 15% Tuesday …

    Source: BioSpace - Pending
  • Published on Jul 4, 2026

    Which iShares Value ETF Is Better, the Small Cap-Focused IWN or IJJ Targeting Mid-Cap Stocks?

    While the iShares S&P Mid-Cap 400 Value ETF (IJJ 0.01%) focuses on mid-sized companies, the iShares Russell 2000 Value ETF (IWN 0.17%) offers exposure to small-cap value stocks with a broader portfolio and slightly higher costs. Both ETFs provide low- …

    Source: The Motley Fool USA - Neutral
  • Published on Jun 13, 2026

    Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment

    Cytokinetics (NASDAQ:CYTK) is one of the most promising mid-cap stocks to buy according to analysts. On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive …

    Source: Yahoo Finance - Center-left
  • Published on Jul 3, 2026

    9 Cardiology Headlines You Missed in Q2 2026

    The second quarter of 2026 saw an influx of major cardiology news, with the US Food and Drug Administration (FDA) approving some significantly beneficial drugs and a slew of conferences providing key clinician insights into ongoing and completed trials. …

    Source: Consultant Live - Pending
  • Published on Jun 25, 2026

    3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

    Large-cap pharma is back in the deal market. AbbVie’s (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets. Patent cliffs approach, GLP-1 franchises crowd in, …

    Source: 24/7 Wall St. - Neutral
  • Published on Jun 21, 2026

    Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

    Welcome back to Don't Miss a Beat! Finerenone's expansion into non-diabetic kidney disease is prompting a broader rethink of how chronic kidney disease is measured, mechanistically understood, and treated across its many causes. On an episode of …

    Source: Consultant Live - Pending
  • Published on Jun 17, 2026

    Edgewise heart drug passes key trial test

    Dive Brief: Edgewise Therapeutics said its experimental heart disease drug hit the goals of a Phase 2 clinical trial, reducing signs of disease and biological markers in two types of cardiomyopathy and supporting advancement of the medicine into pivotal …

    Source: BioPharma Dive - Pending
  • Published on Jun 18, 2026

    Phase 3 HCM Drug Offers Promising Results in Exercise Tests

    TOPLINE: Patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who received aficamten for 24 weeks showed significant improvements in exercise capacity, postexercise recovery, and overall exercise performance compared with those who …

    Source: Medscape - Neutral
  • Published on Jun 13, 2026

    Top Analyst Reports for Costco, Lam Research & KLA

    Friday, June 12, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp. (COST), Lam Research Corp. (LRCX) and KLA …

    Source: Nasdaq - Neutral
  • Published on Jun 16, 2026

    Edgewise shares slip after heart-disease drug trial data disappoints investors

    June 16 (Reuters) – Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of ​investor expectations. The Boulder, Colorado-based company was testing the ‌drug EDG- …

    Source: KDAL - Minnesota - Pending
  • «
  • 1
  • »

06 days 18:04:47

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
search news using your own keywords. There are 924,940,185 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Companies A-Z >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 06/12/2026

World Media Directory >

Companies Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Companies Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Company News Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow EIN Presswire on Facebook, LinkedIn and Substack

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2026 Newsmatics Inc. · All Rights Reserved · General Terms & Conditions · Privacy Policy · Cookie Settings

By continuing to use this site, you agree to our Terms & Conditions, last updated on September 30, 2025.